Apr 2 |
MIRA Making Strides Toward Breakthrough Treatment
|
Apr 2 |
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
|
Mar 21 |
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
|
Feb 6 |
Is MIRA Pharmaceuticals (NASDAQ:MIRA) In A Good Position To Deliver On Growth Plans?
|
Feb 5 |
MIRA Pharmaceuticals Provides Corporate Update
|
Jan 29 |
IPO Roundup: Amer Sports, FibroBiologics, and more
|
Dec 18 |
MIRA Pharmaceuticals files to sell up to 1.7M shares for holders
|
Nov 29 |
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
|
Nov 27 |
MIRA Makes Great Deal for Potential Blockbuster
|
Nov 21 |
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
|